Skip to contentC
CV Sciences, Inc.
C
CVSICV Sciences, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.87M$3.87Mderived−22.1% vs Q4 2021 Net Income-$2.31M-$2.31MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CV Sciences, Inc. · CIK 1510964 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,562,000−3.0% Operating Incomederived-$2,125,000N/M Operating Cash Flowderived$210,000N/M Free Cash Flowderived$210,000N/M Margins · derivedGross margin40.4%+8.0 pt vs Q4 2021
Operating margin-54.9%+123.0 pt vs Q4 2021
Net margin-59.8%+118.5 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 30, 2023 · 89 d after period end